- Opinion
- [Desk’s View] On resolving the stock shortage of drugs
- by Lee, Tak-Sun Dec 5, 2023 05:49am
- As a parent, I feel like I've been visiting hospitals after the endemic than I did during the COVID-19 pandemic. At the height of the pandemic, I only had to worry about COVID-19, but after the pandemic has passed, children with weak immunity are suffering from various viral diseases including colds, flu, and adenovirus. When my older daught
- Company
- AbbVie Korea strengthens its autoimmune disease pipeline
- by Eo, Yun-Ho Dec 5, 2023 05:48am
- AbbVie Korea is actively working to advance its position in the field of autoimmune diseases. According to industry sources, AbbVie Korea successfully expanded the indications for its Interleukin-23(IL-23) inhibitor 'SKYRIZI (Risankizumab)’ and JAK inhibitor ‘RINVOQ (Upadacitinib).’ On November 15th, an indication was added for SKY
- Company
- Companies in KOR and abroad compete in Eylea biosimilar mkt
- by Son, Hyung-Min Dec 5, 2023 05:48am
- Intense challenges are being made against Bayer's Eylea, the current leader in the macular degeneration market. Not only domestic biosimilar companies like Celltrion and Samsung Bioepis but also traditional pharmaceutical companies such as Sam Chun Dang Pharm have thrown down the gauntlet. Bayer and Regeneron, the original developers of
- InterView
- 'Janssen’s strong in autoimmune diseases for a reason'
- by Eo, Yun-Ho Dec 5, 2023 05:48am
- Most pharmaceutical companies have one business unit that represents the company. These units, which usually own specialized cardiovascular, anticancer, or antiviral products, or have flagship products that lead their respective markets, are often revered within the company as well. Janssen Korea’s Immunology Business Unit is one such
- Policy
- MOHW will expand drugs subject to price adjustments
- by Lee, Tak-Sun Dec 5, 2023 05:48am
- To ensure higher drug prices for medicines in short supply, the Ministry of Health and Welfare (MOHW) announced its plan to revise the evaluation standard for drugs eligible to apply for pricing adjustments to increase the upper limit price (list price). Accordingly, national essential drugs and those selected by public-private consult
- Company
- Celltrion applies for US approval of its Prolia biosimilar
- by Chon, Seung-Hyun Dec 4, 2023 05:13am
- Celltrion announced today that it has filed an application for the marketing authorization of its, ‘CT-P41,’ to the US Food and Drug Administration (FDA). CT-P41 is a biosimilar of ‘Prolia,’ a treatment for osteoporosis. Based on the results of a global Phase III clinical trial on CT-P41, Celltrion filed for marketing authorization of
- Policy
- Tagrisso and Leclaza complete drug pricing negotiations
- by Lee, Tak-Sun Dec 4, 2023 05:13am
- The National Health Insurance Serivce was found to have completed pricing negotiations with the companies for the reimbursement of Tagrisso (AZ, osimertinib) and Leclaza (Yuhan, lasertinib) as first-line treatments for non-small cell lung cancer through the risk-sharing agreement (RSA) system. However, as the two were applied different t
- Opinion
- [Reporter's View] Non-face-to-face treatment pilot project
- by Lee, Jeong-Hwan Dec 4, 2023 05:12am
- Starting December 15th, ’24-hour non-face-to-face treatment’ will be available to the public following the legalization of revised non-face-to-face treatment pilot project by the Ministry of Health and Welfare. The project will extend the non-fact-to-face treatment benefit that had been previously limited to returning patients to new pat
- Policy
- Preferential pricing plan will be further discussed by HIPDC
- by Lee, Tak-Sun Dec 4, 2023 05:12am
- The government’s announcement of the plan to improve Korea’s drug pricing system to properly compensate for the innovation value of new drugs (hereinafter referred to as the New Drug Preference Pricing Plan) is expected to be made around the end of this month. The plan was originally set to be presented for deliberation at the general m
- Company
- Pharma companies fiercely compete to develop ADC drugs
- by Son, Hyung-Min Dec 1, 2023 05:35am
- Competition among domestic pharmaceutical companies to secure new antibody-drug conjugate (ADC) technology has been intensifying in Korea. With ADC drugs recently demonstrating an effect on various cancer types, there is an analysis that the industry is making active measures to secure new ADC technologies. According to the pharmaceutical
